Piper Sandler Maintains Overweight on Amgen, Lowers Price Target to $427

Benzinga Newsdesk www.benzinga.com Negative 90.6%

Neg 90.6% Neu 0% Pos 0%

Piper Sandler analyst David Amsellem maintains Amgen (NASDAQ:AMGN) with a Overweight and lowers the price target from $432 to $427.